Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

NeoGenomics, Inc. NEO

Healthcare  —  Diagnostics & Research
19.33 (0.23) (1.18%) as of 25 Sep
Market cap
$2.5B
P/E
0.0×
Revenue Champion (10y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

NeoGenomics, Inc. (NEO) Business Profile

Updated before January 2025

Company Overview

NeoGenomics, Inc. (NEO) is a leading provider of cancer-focused genetic testing services and global oncology contract research services. Founded in 2001 by Dr. Michael Dent, the company is headquartered in Fort Myers, Florida, and has grown to become a prominent player in the precision medicine and oncology diagnostics space. NeoGenomics operates with a mission to improve patient care by providing high-quality, innovative diagnostic services that enable better treatment decisions. The company is led by a team of experienced executives, including Chris Smith, who serves as the Chief Executive Officer, and Douglas Brown, the Chief Financial Officer. Their leadership has been instrumental in driving the company’s growth and innovation in the field of oncology diagnostics.

Core Business Segments

NeoGenomics operates through two primary business segments:

Clinical Services

This segment focuses on providing diagnostic testing services to oncologists, pathologists, hospitals, and other healthcare providers. Key offerings include:

  • Molecular Testing: Advanced genetic and molecular testing services to identify specific cancer mutations and biomarkers.
  • Flow Cytometry: A diagnostic tool used to analyze the physical and chemical characteristics of cells or particles.
  • Cytogenetics: Chromosomal analysis to detect genetic abnormalities associated with cancer.
  • Immunohistochemistry (IHC): A technique used to identify specific antigens in cells, aiding in cancer diagnosis and classification.
  • Next-Generation Sequencing (NGS): Comprehensive genomic profiling to identify actionable mutations for targeted therapies.

Pharma Services

This segment provides contract research services to pharmaceutical and biotechnology companies. Key offerings include:

  • Clinical Trials Support: Assisting in the design and execution of oncology-focused clinical trials.
  • Companion Diagnostics Development: Developing diagnostic tests that help identify patients who are most likely to benefit from specific therapies.
  • Biomarker Discovery: Identifying and validating biomarkers for use in drug development and personalized medicine.
  • Laboratory Services: Providing state-of-the-art laboratory facilities for research and testing.

Business Model

NeoGenomics operates on a hybrid business model that integrates its clinical and pharma services to create a comprehensive oncology diagnostics ecosystem. The company generates revenue through:

  • Diagnostic Testing Fees: Payments from healthcare providers, insurance companies, and patients for clinical testing services.
  • Contract Research Agreements: Revenue from pharmaceutical and biotech companies for research and development services.
  • Partnerships and Collaborations: Strategic alliances with other healthcare organizations to expand service offerings and market reach.

By leveraging its expertise in both clinical diagnostics and pharmaceutical research, NeoGenomics aims to provide end-to-end solutions that address the needs of patients, healthcare providers, and drug developers.

Strategic Direction

NeoGenomics is focused on several strategic initiatives to drive future growth:

  • Expansion of Service Offerings: The company is investing in new technologies and capabilities, such as liquid biopsy and artificial intelligence, to enhance its diagnostic portfolio.
  • Global Expansion: NeoGenomics is actively expanding its presence in international markets, particularly in Europe and Asia, to tap into growing demand for oncology diagnostics.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable practices in its operations and supply chain.
  • Innovation in Precision Medicine: NeoGenomics is at the forefront of developing personalized medicine solutions, including companion diagnostics and biomarker-driven therapies.

Competitive Landscape

NeoGenomics operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Quest Diagnostics: A leading provider of diagnostic information services.
  • LabCorp: A global life sciences company offering comprehensive clinical laboratory services.
  • Foundation Medicine: Specializes in molecular information and comprehensive genomic profiling.
  • Caris Life Sciences: Focuses on precision medicine and molecular profiling.
  • Myriad Genetics: Known for its genetic testing and precision medicine solutions.

Despite the competition, NeoGenomics differentiates itself through its focus on oncology, advanced technology, and strong customer relationships.

Risk Factors

NeoGenomics faces several risks that could impact its business:

  • Market Dependence: The company’s revenue is heavily reliant on the oncology diagnostics market, making it vulnerable to market fluctuations.
  • Regulatory Challenges: Compliance with stringent healthcare regulations and approval processes can be time-consuming and costly.
  • Supply Chain Disruptions: Dependence on third-party suppliers for reagents and equipment poses a risk of supply chain interruptions.
  • Technological Obsolescence: Rapid advancements in diagnostic technologies could render existing products and services obsolete.
  • Economic Conditions: Changes in healthcare spending and insurance reimbursement policies could affect demand for the company’s services.

Recent Developments

NeoGenomics has made significant strides in recent years:

  • Launch of Liquid Biopsy Tests: The company introduced liquid biopsy tests to provide non-invasive cancer diagnostics.
  • Acquisition of Inivata: This acquisition strengthened NeoGenomics’ capabilities in liquid biopsy and minimal residual disease testing.
  • Partnerships with Pharma Companies: NeoGenomics has entered into strategic collaborations with leading pharmaceutical companies to develop companion diagnostics.
  • COVID-19 Impact: The pandemic accelerated the adoption of telemedicine and remote diagnostics, creating new opportunities for the company.

Investment Considerations

Strengths

  • Market Leadership: NeoGenomics is a recognized leader in oncology diagnostics.
  • Comprehensive Service Portfolio: The company offers a wide range of diagnostic and research services.
  • Strong Growth Potential: Increasing demand for precision medicine and personalized therapies presents significant growth opportunities.
  • Experienced Leadership: A seasoned management team with a proven track record of success.

Risks

  • High Competition: Intense competition from established players and new entrants.
  • Regulatory Risks: Potential delays or denials in regulatory approvals.
  • Economic Uncertainty: Vulnerability to changes in healthcare spending and reimbursement policies.

Conclusion

NeoGenomics, Inc. is well-positioned to capitalize on the growing demand for oncology diagnostics and precision medicine. With a strong focus on innovation, strategic partnerships, and global expansion, the company is poised for long-term growth. However, investors should carefully consider the risks associated with market competition, regulatory challenges, and economic conditions. Overall, NeoGenomics remains a compelling player in the rapidly evolving field of cancer diagnostics and personalized medicine.